Abstract
The series of deaza analogs of folic acid has been a rich source of compounds of interest as potential antitumor drugs.1 The mode of action of these compounds is, however, related to structure in ways not yet fully understood. For example, DDATHF2 is a specific inhibitor of glycinamide ribonucleotide formyl transferase (GARFT)3 while the related pyrrolo[2,3-d]pyrimidine-based analog, LY231514, has been found to inhibit thymidylate synthase (TS) 4 Both (6R)-DDATHF (lometrexol)5 and LY2315146 have shown promising in vivo antitumor activity against a variety of murine and human tumor cell lines and are currently undergoing clinical evaluation. LY288601 may be viewed as a hybrid structure which possesses both the ring saturation of DDATHF and the 6,5-heterocyclic ring system of the pyrrolo[2,3-d]pyrimidine-based LY231514. LY288601 was first described by Akimoto and coworkers7 (as Takeda T-41440) but only limited cytotoxicity data has been reported.8 We report here a convenient alternate synthesis of LY288601, the results of cell culture cytotoxicity and reversal experiments, and in vivo antitumor evaluation of this compound in comparison with DDATHF and LY231514.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
For a recent overview of the status of antifolate research related to antitumor therapy see: E. M. Berman and L. M. Werbel, J. Med. Chem. 34:479 (1991) and references cited therein.
E. C. Taylor, P. J. Harrington, S. R. Fletcher, G. P. Beardsley, and R. G. Moran, J. Med. Chem. 28:914(1985).
R. G. Moran, S. W. Baldwin, E. C. Taylor, and C. Shih, J. Biol. Chem. 264:21047 (1989).
E. C. Taylor, D. Kuhnt, C. Shih, S. M. Rinzel, G. B. Grindey, J. Barredo, M. Jannatipour, and R. G. Moran, J. Med. Chem. 35:4450 (1992).
C. Shih, G. B. Grindey, P. J. Houghton, and J. A. Houghton, Proc. Am. Assn. for Cancer Research ,29:abstr. 1125 (1988).
G. B. Grindey, C. Shih, C. J. Barnett, H. L. Pearce, J. A. Engelhardt, G. C. Todd, S. M. Rinzel, J. F. Worzalla, L. S. Gossett, T. P. Everson, T. M. Wilson, M. E. Kobierski, M. A. Winter, J. R. Bewley, D. Kuhnt, E. C. Taylor, and R. G. Moran, Proc. Am. Assn. for Cancer Research ,33:abstr. 2451 (1992).
H. Akimoto, H. Takenori, and T. Miwa, European Patent Appl. 334 636 A2 (1989).
IC50 0.32 μg/ml vs KB cells. H. Akimoto, T. Hitaka, T. Miwa, K. Yukishige, T. Kusanagi, and K. Ootsu, Proc. Am. Assn. for Cancer Research 32:abstr. 1938 (1991).
Full experimental details of the synthetic work presented here will be published separately. C. J. Bamett and T. M. Wilson, Heterocycles ,in press.
E. C. Taylor, P. Gillespie, and M. Patel, J. Org. Chem. 57:3218 (1992).
W. Lehnert, Tetrahedron Lett. 4723 (1970).
Z. J. Kaminski, Tetrahedron Lett. 26:2901 (1985).
G. P. Beardsley, B. Moroson, E. C. Taylor, and R. G. Moran, J. Biol. Chem. 264:328 (1989).
R. G. Moran, personal communication. We thank Professor Moran for the TS inhibition measurement on LY288601.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Barnett, C.J., Wilson, T.M., Grindey, G.B. (1993). Synthesis and Antitumor Activity of LY288601, the 5,6-Dihydro Analog of LY231514. In: Ayling, J.E., Nair, M.G., Baugh, C.M. (eds) Chemistry and Biology of Pteridines and Folates. Advances in Experimental Medicine and Biology, vol 338. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2960-6_81
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2960-6_81
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6287-6
Online ISBN: 978-1-4615-2960-6
eBook Packages: Springer Book Archive